Special Issue "New Advances for the Application of Liquid Biopsies to Manage Cancer Patients"
Deadline for manuscript submissions: 30 September 2021.
Interests: gynecological oncology; endometrial cancer; liquid biopsy; circulating tumor cells; ctDNA
In the last decade, the introduction of precision medicine has revolutionized the oncology field. As part of this new philosophy to fight cancer, liquid biopsies have emerged as a novel tool in medical oncology which has opened new horizons for improving clinical decision making. Tumors release several biomolecules into body fluids that can be used as biomarkers for diagnosis, prognosis, therapy selection, and monitoring. Therefore, although blood is the most widely used type of liquid biopsy, other fluids such as urine, pleural fluid, or saliva can provide valuable information for management of cancer patients. Nowadays, analyses of tissue biopsies still remain the gold standard for diagnosis; however, these analyses have limitations in reflecting tumoral heterogeneity and evolution, which can be improved upon using liquid biopsies.
This Special Issue aims to include original research articles and reviews demonstrating the value of circulating biomarkers for improving cancer management in terms of an early diagnosis, personalized therapy, and dynamic monitoring. To achieve this goal, we will focus on relevant data regarding the clinical interest in circulating tumor cells (CTCs), circulating nucleic acids (ctDNA/ctRNA), and circulating extracellular vesicles (cEVs) in the context of solid tumors.
Dr. Laura Muinelo-Romay
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- liquid biopsy
- circulating tumor cells (CTCs)
- circulating tumor DNA (ctDNA)
- circulating tumor RNA (ctRNA)
- circulating extracellular vesicles (cEVs)
- cancer diagnosis
- therapy selection/monitoring